To the editor: We thank Drs. Kane and Becker for their interest on the TEDDY study [1, 2] . Our study aimed to know the long-term safety of anti-TNF agents in children born to mothers with inflammatory bowel disease (IBD). The safety of these drugs during pregnancy has been demonstrated; however, little is known about their impact on children outcomes. For that reason, we hope that TEDDY study could bring some data to mothers and clinicians to make evidence-based decisions. However, we think that the TEDDY study is only the first step in a long way to go. IBD affects patients in their reproductive years. To maintain disease in remission is crucial for pregnancy outcome. In the previous years, new biologics have been approved for the treatment of IBD: vedolizumab for Crohn's disease and ulcerative colitis, and ustekinumab for Crohn's disease. Recently, a JAK inhibitor-tofacitinib-has been approved for ulcerative colitis. In the near future, new drugs are expected to increase the therapeutic armamentarium of IBD. All these drugs will be increasingly used in clinical practice and, therefore, patients will wish to become pregnant while receiving those treatments.
In consequence, it is an urgent need to get information about the safety of those new treatments during pregnancy and in children development. In addition, special situations such as multiple gestations should also be considered, as their outcome in IBD is largely unknown. To that aim, prospective multicenter registries are warranted and eagerly awaited.
